Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
201 hedge funds and large institutions have $3.07B invested in Global Blood Therapeutics, Inc. in 2019 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 64 increasing their positions, 75 reducing their positions, and 19 closing their positions.
176% more call options, than puts
Call options by funds: $83.1M | Put options by funds: $30.2M
63% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 19
32% more capital invested
Capital invested by funds: $2.33B → $3.07B (+$739M)
6% more funds holding
Funds holding: 190 → 201 (+11)
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
15% less repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 75
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$29.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$22.7M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$16.5M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.5M |
| 5 |
State Street
Boston,
Massachusetts
|
+$10.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$22.1M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$22.1M |
| 3 |
Citigroup
New York
|
-$10.4M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$10.2M |
| 5 |
TA
Teachers Advisors
New York
|
-$10.1M |
GBT Hedge Fund Activity: Q1 2019 in Review
201 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q1 2019, worth a combined $3.07B — up 32% from $2.33B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new GBT positions and 19 closed out — a net gain of 12 holders — while 64 added to existing stakes and 75 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $29.5M. The largest seller was Boxer Capital, cutting an estimated $22.1M.
- 201 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q1 2019, up from 190 in Q4 2018.
- Funds reported $3.07B of Global Blood Therapeutics, Inc. stock for Q1 2019, up 32% quarter-over-quarter.
- 31 funds opened new Global Blood Therapeutics, Inc. positions in Q1 2019 and 19 closed out, a net change of +12 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q1 2019 was Avoro Capital Advisors, an estimated $29.5M added.
- The largest Global Blood Therapeutics, Inc. seller in Q1 2019 was Boxer Capital, an estimated $22.1M sold.
Based on aggregated 13F filings for Q1 2019.